Financials Korro Bio, Inc.

Equities

KRRO

US5009461089

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-24 pm EDT 5-day change 1st Jan Change
48.85 USD +1.60% Intraday chart for Korro Bio, Inc. -10.63% +1.92%

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 383.3 453 - -
Enterprise Value (EV) 1 383.3 453 453 453
P/E ratio -0.9 x -5.07 x -5.18 x -5.92 x
Yield - - - -
Capitalization / Revenue - - - -
EV / Revenue - - - -
EV / EBITDA - - - -
EV / FCF -5.1 x -5.18 x -4.77 x -4.27 x
FCF Yield -19.6% -19.3% -21% -23.4%
Price to Book - - - -
Nbr of stocks (in thousands) 7,997 9,273 - -
Reference price 2 47.93 48.85 48.85 48.85
Announcement Date 3/26/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - - - - -
EBITDA - - - - -
EBIT 1 - -84.53 -86.3 -95.42 -101.8
Operating Margin - - - - -
Earnings before Tax (EBT) 1 -58.02 -81.14 -81.12 -92.65 -101.8
Net income 1 -58.03 -81.17 -81.16 -92.65 -101.8
Net margin - - - - -
EPS 2 - -53.08 -9.640 -9.437 -8.250
Free Cash Flow 1 - -75.12 -87.5 -95 -106
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 7/27/23 3/26/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - - - - -
EBITDA - - - - - - -
EBIT 1 -26.89 -21.45 -20.91 -21.28 -21.91 -22.5 -23.12
Operating Margin - - - - - - -
Earnings before Tax (EBT) 1 -25.4 -19.54 -20.33 -20.51 -21.22 -21.88 -22.6
Net income 1 -25.43 -19.56 -20.34 -20.51 -21.22 -21.88 -22.6
Net margin - - - - - - -
EPS 2 -43.10 -2.440 -2.395 -2.340 -2.465 -2.600 -2.480
Dividend per Share - - - - - - -
Announcement Date 3/26/24 5/14/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 - -75.1 -87.5 -95 -106
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex 1 - 7.84 5 5 -
Capex / Sales - - - - -
Announcement Date 7/27/23 3/26/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
48.85 USD
Average target price
126.2 USD
Spread / Average Target
+158.44%
Consensus
  1. Stock Market
  2. Equities
  3. KRRO Stock
  4. Financials Korro Bio, Inc.